Drug · CHEMBL1568

FLUDARABINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. FLUDARABINE. Drugs and targets, record CHEMBL1568. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1568

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: FLUDARABINE; ChEMBL
ChEMBL ID: CHEMBL1568; ChEMBL
Type: Small molecule; ChEMBL
Other names: 2-f-araa, 2-fluoro ara-a, 2-fluorovidarabine, Fludarabina, Fluradosa, NSC-118218, NSC-118218H; ChEMBL
DrugBank: DB01073; DrugBank
InChIKey: HBUBKKRHXORPQB-FJFJXFQQSA-N; ChEMBL
Open Targets' highest stage: Approval, for 1 of its 246 diseases, from ClinicalTrials.gov; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases246

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
acute myeloid leukemia	Phase 3	ClinicalTrials.gov	198	198	https://conductscience.org/library/drugs?q=MONDO_0018874
myelodysplastic syndrome	Phase 3	ClinicalTrials.gov	126	126	https://conductscience.org/library/drugs?q=MONDO_0018881
B-cell chronic lymphocytic leukemia	Phase 3	ClinicalTrials.gov	119	119	https://conductscience.org/library/drugs?q=MONDO_0004948
acute lymphoblastic leukemia	Phase 3	ClinicalTrials.gov	93	93	https://conductscience.org/library/drugs?q=MONDO_0004967
hematopoietic and lymphoid cell neoplasm	Phase 3	ClinicalTrials.gov	74	74	https://conductscience.org/library/drugs?q=MONDO_0044881
non-Hodgkin lymphoma	Phase 3	ClinicalTrials.gov	60	60	https://conductscience.org/library/drugs?q=MONDO_0018908
plasma cell myeloma	Phase 3	ClinicalTrials.gov	58	58	https://conductscience.org/library/drugs?q=MONDO_0009693
melanoma	Phase 2	ClinicalTrials.gov	47	47	https://conductscience.org/library/drugs?q=MONDO_0005105
lymphoma	Phase 2	ClinicalTrials.gov	43	43	https://conductscience.org/library/drugs?q=MONDO_0005062
chronic myeloid leukemia	Phase 3	ClinicalTrials.gov	33	33	https://conductscience.org/library/drugs?q=MONDO_0011996

1 to 10 of 246Source Open Targets

See all 246 diseases

Trials1,126

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01905943	A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia	Phase 3	979	2018-10-29	fludarabine	Its name	ClinicalTrials.gov
NCT01119066	HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies	Phase 2	422	2022-08-05	fludarabine	Its name	ClinicalTrials.gov
NCT02421939	A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation	Phase 3	371	2019-10-17	fludarabine	Its name	ClinicalTrials.gov
NCT00824265	Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia	Phase 3	365	2016-07-25	fludarabine	Its name	ClinicalTrials.gov
NCT03391466	Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma	Phase 3	359	2024-03-07	fludarabine	Its name	ClinicalTrials.gov
NCT00303719	Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy	Phase 2	342	2020-05-12	fludarabine	Its name	ClinicalTrials.gov
NCT00086580	Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients	Phase 3	335	2011-08-11	fludarabine	Its name	ClinicalTrials.gov
NCT01564784	A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia	Phase 3	326	2018-01-17	fludarabine	Its name	ClinicalTrials.gov
NCT00703820	Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia	Phase 3	324	2018-04-02	fludarabine	Its name	ClinicalTrials.gov
NCT00305682	Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant	Phase 2	295	2020-11-02	fludarabine	Its name	ClinicalTrials.gov

1 to 10 of 1,126

See all 1,126 trials

Comparisons in its trials215

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Gilteritinib vs Salvage Chemotherapy: deaths from any cause	204 of 247	96 of 124	371	NCT02421939	Trial comparisons
Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects vs Fludarabine + Cyclophosphamide_ ITT Subjects: Number of Participants With at Least One Grade 3/Grade 4 Myelosuppression Adverse Events	126 of 181	118 of 178	359	NCT00824265	Trial comparisons
Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects vs Fludarabine + Cyclophosphamide_ ITT Subjects: Number of Participants With Autoimmune Hemolytic Anaemia (AIHA)	3 of 181	2 of 178	359	NCT00824265	Trial comparisons
Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects vs Fludarabine + Cyclophosphamide_ ITT Subjects: deaths from any cause	40 of 181	42 of 178	359	NCT00824265	Trial comparisons
Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects vs Fludarabine + Cyclophosphamide_ ITT Subjects: serious adverse events	108 of 181	86 of 178	359	NCT00824265	Trial comparisons
Gilteritinib vs Salvage Chemotherapy: serious adverse events	211 of 246	34 of 109	355	NCT02421939	Trial comparisons
Combination Arm (FluCAM) vs Fludarabine Alone: Participants With Minimal Residual Disease (MRD)	6 of 168	0 of 167	335	NCT00086580	Trial comparisons
Combination Arm (FluCAM) vs Fludarabine Alone: serious adverse events	54 of 164	41 of 165	329	NCT00086580	Trial comparisons
Inotuzumab Ozogamicin vs Defined Investigator's Choice of Chemotherapy: serious adverse events	85 of 164	72 of 143	307	NCT01564784	Trial comparisons
High Risk Patients vs Standard Risk Patients: Acute Graft-Versus-Host Disease	2 of 13	79 of 292	305	NCT00303719	Trial comparisons

1 to 10 of 215

See all 215 comparisons in its trials

Papers from its trials632

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42266673	RESULT	1	PubMed
40209059	RESULT	1	PubMed
39998301	RESULT	1	PubMed
39998298	RESULT	1	PubMed
39846249	RESULT	1	PubMed
39672025	RESULT	1	PubMed
39471440	RESULT	1	PubMed
38821083	RESULT	1	PubMed
38643278	RESULT	1	PubMed
38602546	RESULT	1	PubMed

1 to 10 of 632

See all 632 papers from its trials

Tests in its trials2

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Trail Making Test A	1	0	ConductCognition
Trail Making Test B	1	0	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL1568

GET https://conductscience.org/api/drugs/v1/CHEMBL1568/diseases?page=2

API reference For AI assistants